Answer
DAXAS (roflumilast) is indicated as add-on maintenance treatment to bronchodilators in adults with severe COPD (post-bronchodilator FEV1 below 50% predicted), associated with chronic bronchitis and a history of frequent exacerbations.
Sources for this answer
- DAXAS 500 micrograms film-coated tabletsAstraZeneca UK Limited · emc · SmPC §4.1 Therapeutic Indications · Version 16Document updated
Sources checked